NCT01270698 (Clinical Trial/ Labetuzumab-SN-38 / IMMU-130 / hMN-14-SN38)

Study Title
Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer (NCT01270698)

Trial Description
This is a Phase I trial to study the safety of IMMU-130 (also known as labetuzumab-SN-38 or hMN-14-SN38). IMMU-130 is composed of a drug attached to an antibody. The drug is the active ingredient in irinotecan which is a common chemotherapy drug used for colorectal cancer. Antibodies are proteins normally made by the immune system. They bind to substances that don’t belong in the body to prevent harm to the body.

The antibody in this study was designed to bind to a marker located on colorectal cancer tumors. The antibody was originally made from mouse proteins, but was changed in the laboratory to be more like human antibodies. This study will investigate how IMMU-130 acts for the treatment of colorectal cancer. The study is mainly being done to see if IMMU-130 is safe.

This trial is sponsored by Immunomedics. [1]

Study Data

  • Condition: Colorectal Cancer
  • Interventions:
    • Drugs used in this trial
      • IMMU-130 (Labetuzumab-SN-38; IMMU-130; hMN-14-SN38)
  • Phase: I
  • Enrollment: 26
  • Start: May 2011
  • Completion: December 2014
  • Last verified: January 2015

Study Schematic 

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 10, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.